Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.
about
Cancer-treatment-induced neurotoxicity--focus on newer treatmentsImpaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with CarboplatinChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsGhrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating Repair of DNA Double Strand Breaks Through Activation of p53 in Mice.Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male miceCisplatin inhibits hippocampal cell proliferation and alters the expression of apoptotic genes.Cancer chemotherapy impairs contextual but not cue-specific fear memoryTherapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusionImpact of the 1000 genomes project on the next wave of pharmacogenomic discoveryNorth Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled studyCentral neurotoxicity in cancer chemotherapy: pharmacogenetic insights.Nurse self-evaluation of assessment of chemotherapy-induced peripheral neuropathy in patients with cancer.Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases.Neurotoxicity of cancer chemotherapy.Nicotinamide inhibits alkylating agent-induced apoptotic neurodegeneration in the developing rat brainHigh cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.Autonomic dysfunction in patients with advanced cancer; prevalence, clinical correlates and challenges in assessmentA framework for assessment in oncology rehabilitation.Long-term aerobic exercise protects against cisplatin-induced nephrotoxicity by modulating the expression of IL-6 and HO-1.Considerations for Training Cancer SurvivorsTumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted.Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants.A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.Neuropsychological care and rehabilitation of cancer patients with chemobrain: strategies for evaluation and intervention development.Terminal arbor degeneration--a novel lesion produced by the antineoplastic agent paclitaxel.Neurosteroid 3α-androstanediol efficiently counteracts paclitaxel-induced peripheral neuropathy and painful symptomsThe Relationship between Visuospatial Memory and Coping Strategies in Breast Cancer Survivors.Conducting cancer control and survivorship research via cooperative groups: a report from the American Society of Preventive Oncology.Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral neuropathy in women after breast cancer treatment.Platinum-induced neurotoxicity and preventive strategies: past, present, and futurePrevalence, types, clinical associations, and determinants of peripheral neuropathy in rheumatoid patientsPrescribed drugs and neurological complicationsSelf-reported memory problems in adult-onset cancer survivors: effects of cardiovascular disease and insomniaCharacterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure.Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.Candidate mechanisms for chemotherapy-induced cognitive changes.The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.
P2860
Q26782604-F2CCF4ED-DFF8-440C-85DA-C3C41BBFF67DQ27300384-A1FC35E0-C5B4-46B1-90C4-4793A6D249EBQ28079705-C5ADB3F8-E98B-4DC9-A8AF-81AE70E1C0F8Q30357873-1F9C7472-77CA-4A73-B965-11440E2EEBF1Q30410972-7430310A-ED66-43E4-93A2-F9B97DA8D376Q30413236-6643CDD5-67BD-43E8-B122-6FB67C1EF5BDQ30438754-1CE32992-C7B3-41C2-8C6B-4D261384F45AQ30478959-7F046EFC-2CAB-4F76-B6A4-665C9EF86B47Q33590378-8D1A1DB4-47BB-4892-B3BB-1FF6C3F5EB54Q33708200-79A285F3-B223-4889-AA18-3262EF12DB91Q33717608-790761EA-FA56-4A46-BC54-2E038E475EBDQ33857581-67552A48-90E1-4850-B90C-7F7FEB454F26Q33885675-A8EA9C2C-980C-4CD3-A925-FBB39652A253Q33984071-DDC1ABBD-58C6-4895-924B-5D7899DEE11CQ34028842-FF1326FB-FF73-4BCB-88C2-7D33DC911A14Q34094753-CFDDE927-68A3-4270-AEA7-133BD982A4CBQ34098881-D4760BFD-A5E1-4A8F-97F9-E93F9BE127A2Q34150967-8420901A-9322-4165-9B3E-6379BA491412Q34179851-CD904177-6560-428D-B6FE-E1338AFC68CBQ34259686-0FF2D155-CEF5-4B83-A355-B7B96E65559CQ34278172-5C526B10-EAAF-47F6-8FC9-A4167B6280F8Q34285948-13369C1B-5810-4210-8ED1-BBC6D3D51CB7Q34394131-5413881C-DD29-45F8-9EBE-DCD35F4D30B6Q34592925-34403508-AF5B-4D5E-9AE9-9C0A0F349512Q34619839-D46E0521-555F-4E1C-B16D-105D76D8192AQ34633028-7F4A442F-301A-497B-B0D3-849A3668A3E5Q34917256-5E3646FE-9327-43EF-BFB0-84C5B9264D77Q35049356-772362B4-764E-456A-9A26-20424A2A2DDBQ35052530-E08DC8A4-82F7-4C05-8D7E-7B33A13DC44BQ35072010-DDDFB0A1-2ED8-4053-BC71-2BF0D1579920Q35202129-E568AA2A-5188-4D10-BCBD-4E75FB55A4CBQ35345734-7DB0CC76-582A-47F7-B004-EA3E376A6DC8Q35430496-D454BE35-BB49-4E38-8EDC-F1A851CAC876Q35576530-2B300B5A-8F50-4403-8208-4DD2406861D3Q35738596-EC9E76D4-6EC1-452D-8568-3FD1B16BE66AQ35740234-D98E541D-5AE4-452B-BE44-2A37E69F1A51Q35815721-7B6DE3CD-64F2-4738-8E12-CFF0D07F8271Q35852412-B8954537-6C96-447E-BBBA-363CCCE28F0BQ35898051-806216B9-1688-49C2-94CA-E092716B94A1Q35898601-64288398-1F49-487A-A5F0-F465AB465E6B
P2860
Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Neurotoxic complications of ch ...... signs and optimal management.
@ast
Neurotoxic complications of ch ...... signs and optimal management.
@en
type
label
Neurotoxic complications of ch ...... signs and optimal management.
@ast
Neurotoxic complications of ch ...... signs and optimal management.
@en
prefLabel
Neurotoxic complications of ch ...... signs and optimal management.
@ast
Neurotoxic complications of ch ...... signs and optimal management.
@en
P2093
P1433
P1476
Neurotoxic complications of ch ...... signs and optimal management.
@en
P2093
Carla C P Verstappen
Jan J Heimans
Klaas Hoekman
Tjeerd J Postma
P304
P356
10.2165/00003495-200363150-00003
P577
2003-01-01T00:00:00Z
P6179
1034323022